MetaVia Inc. (MTVA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US64132R5037
MetaVia Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -13.71 m USD |
| EBIT | -12.97 m USD |
| Net income | -12.97 m USD |
| Diluted EPS – continuing operations | -7.35 USD |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
More stocks
- ASTROTECH Corp (ASTC)
- IN8BIO, INC. (INAB)
- Aspira Women's Health Inc. (AWHL)
- P3 Health Partners Inc. (PIII)
- Chinhung International Inc. Pfd. Series 2 (002787.KS)
- Sundance Strategies, Inc. (SUND)
- LIQTECH INTERNATIONAL INC (LIQT)
- T3 Defense Inc. (DFNS)
- SurgePays, Inc. (SURG)
- Magic Empire Global Limited (MEGL)
- WILLAMETTE VALLEY VINEYARDS INC (WVVI)
- YUNHONG GREEN CTI LTD. (YHGJ)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.